The global stomach cancer market size was valued at USD 3.92 billion in 2025 and is projected to grow from USD 4.44 billion in 2026 to USD 12.06 billion by 2034, registering a CAGR of 13.3% during the forecast period from 2026 to 2034. North America dominated the stomach cancer market with a market share of 38.6% in 2025.
Stomach cancer, also known as gastric cancer, is a type of cancer that develops in the lining of the stomach when abnormal cells grow uncontrollably. It commonly begins in the mucus-producing cells of the stomach and may gradually spread to nearby tissues or other parts of the body if left untreated. Risk factors include Helicobacter pylori infection, smoking, unhealthy diet, family history, and chronic stomach inflammation.
Download a Free Sample To learn more about this report,
Growing Use of Biomarker-Based Patient Selection in Stomach Cancer Treatment
The stomach cancer treatment landscape is shifting toward biomarker-defined patient populations, with treatment decisions increasingly linked to molecular characteristics of individual tumors. This is expanding the role of diagnostic testing alongside oncology therapies and supporting more differentiated treatment pathways rather than relying solely on disease stage.
Increasing Emphasis on Population-Level Prevention of Gastric Cancer
The market is also being influenced by a stronger focus on preventing stomach cancer before advanced disease develops. Public-health strategies are increasingly addressing modifiable infectious causes, particularly Helicobacter pylori, through systematic screening and treatment programs, creating greater emphasis on prevention alongside diagnosis and treatment.
Expansion of Perioperative Treatment Increases Demand for Multimodal Cancer Therapies
Treatment demand is being supported by the expansion of systemic therapy into the perioperative setting, where medicines are used before and after surgery to improve disease control. This broadens the role of oncology treatment beyond metastatic disease and increases demand for combination regimens across the treatment pathway.
Late Disease Presentation Limits the Effectiveness of Available Treatment Options
A substantial proportion of stomach cancer is identified after the disease has progressed, which can reduce the feasibility of curative treatment and complicate clinical management. Limited early detection therefore restricts the ability of healthcare systems to intervene before tumors become advanced.
Helicobacter Pylori Eradication Programs Create Opportunities for Earlier Disease Prevention
Expansion of organized H. pylori testing and eradication programs creates an opportunity to reduce future stomach cancer incidence by addressing a major preventable cause before malignant disease develops. Healthcare providers and diagnostic companies can capture this opportunity through screening, diagnostic testing, and treatment-support services.
Rapid Expansion of Treatment Combinations Increases Clinical Management Complexity
The growing number of targeted and immune-based treatment combinations requires clinicians to evaluate tumor characteristics, treatment sequencing, eligibility criteria, and potential adverse effects when selecting therapies. This increases the complexity of developing consistent treatment pathways across healthcare settings.
Adenocarcinoma accounted for the largest share of the global stomach cancer market at 76.4% in 2025, driven by its high prevalence among gastric cancer cases and the increasing availability of targeted therapies and early diagnostic techniques. Rising awareness, improved screening programs, and advancements in precision oncology continue to support the dominance of this segment. Meanwhile, gastrointestinal stromal tumors (GISTs) are expected to witness steady growth due to ongoing developments in molecular diagnostics and targeted treatment options for rare gastric cancers.
Request Customizationto receive a tailored report.
The Immunotherapy segment is projected to expand at the highest CAGR of 12.1% during 2026–2034, supported by increasing approvals of immune checkpoint inhibitors, growing adoption of personalized medicine, and improved clinical outcomes for advanced gastric cancer patients. Rising investments in oncology research and biomarker-based treatment approaches are further accelerating the adoption of immunotherapy. At the same time, chemotherapy continues to hold a significant share of the market, remaining a standard treatment option for patients across multiple stages of stomach cancer, while targeted therapy, radiation therapy, and surgery continue to play important roles in comprehensive disease management.
Hospitals and Specialty Clinics held the largest share of the global stomach cancer market at 69.7% in 2025, owing to the availability of specialized oncology care, advanced diagnostic infrastructure, multidisciplinary treatment teams, and access to innovative therapies. The growing number of cancer treatment centers and increasing patient preference for specialized healthcare facilities continue to strengthen this segment. Meanwhile, Ambulatory Surgery Centers are anticipated to witness healthy growth during the forecast period, supported by the rising adoption of minimally invasive procedures, shorter hospital stays, and cost-effective outpatient cancer care.
Speak to an Analystto discuss market opportunities.
North America dominated the global stomach cancer market with a 38.6% market share, valued at USD 1.51 billion in 2025. The region benefits from advanced healthcare infrastructure, widespread adoption of precision oncology, and strong investments in cancer research and drug development. Increasing use of biomarker-based diagnostics, targeted therapies, and immunotherapies is improving treatment outcomes and supporting market growth. In addition, favorable reimbursement policies, high healthcare spending, and the presence of leading pharmaceutical companies continue to strengthen the region's leadership in the global market.
The United States generated USD 1.18 billion in 2025. The country's market is driven by increasing adoption of personalized cancer therapies, growing investments in clinical trials, and the availability of advanced diagnostic technologies. Rising awareness of early cancer detection, strong regulatory support for innovative oncology drugs, and the presence of major biopharmaceutical companies continue to reinforce the country's leading position in the North American market.
Canada accounted for USD 0.33 billion in 2025. Market growth is supported by universal healthcare coverage, increasing government funding for cancer research, and expanding access to precision medicine. National cancer screening initiatives and the adoption of advanced treatment protocols are further improving patient outcomes and driving demand for innovative stomach cancer therapies.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.4% of the global stomach cancer market, reaching USD 1.07 billion in 2025. The regional market is driven by well-established healthcare systems, increasing investments in oncology research, and expanding adoption of personalized medicine. Government-supported cancer screening programs, rising demand for targeted therapies, and collaborative research initiatives across European countries continue to support market growth and improve access to advanced stomach cancer treatments.
The United Kingdom generated USD 0.24 billion in 2025. The country's market is supported by increasing investments in cancer diagnostics, expanding clinical research, and improved access to innovative oncology treatments through the National Health Service (NHS). Growing emphasis on early diagnosis and personalized treatment strategies is also contributing to market expansion.
Germany accounted for USD 0.31 billion in 2025, making it one of the leading contributors in Europe. Market growth is driven by advanced oncology care, strong pharmaceutical research capabilities, and increasing adoption of precision medicine. Government initiatives promoting early cancer detection and the presence of leading cancer treatment centers further strengthen the country's market position.
Asia Pacific accounted for 23.8% of the global stomach cancer market, valued at USD 0.93 billion in 2025, and is projected to register the fastest CAGR of 11.2% during the forecast period. The regional market is driven by the high incidence of gastric cancer, expanding healthcare infrastructure, and increasing government investments in cancer screening and treatment programs. Growing adoption of advanced diagnostic technologies and targeted therapies, along with rising awareness of early detection, continues to accelerate market growth across the region.
Japan generated USD 0.26 billion in 2025. The country's market is driven by one of the world's most comprehensive gastric cancer screening programs, advanced endoscopic technologies, and widespread adoption of precision oncology. Continuous investments in cancer research and early diagnosis initiatives continue to support market growth.
China accounted for USD 0.39 billion in 2025, making it the largest market in Asia Pacific. Growth is supported by the country's large patient population, increasing healthcare expenditure, expanding access to innovative cancer therapies, and government initiatives focused on improving cancer diagnosis and treatment. Rising investments in biotechnology and oncology research further contribute to market expansion.
The Middle East & Africa represented 4.1% of the global stomach cancer market, totaling USD 0.16 billion in 2025. Market growth is supported by improving healthcare infrastructure, increasing government initiatives for cancer control, and expanding access to specialized oncology services. Rising awareness of early cancer diagnosis and investments in modern diagnostic technologies are also contributing to regional market development.
The United Arab Emirates (UAE) generated USD 0.06 billion in 2025. The market is driven by increasing investments in advanced healthcare infrastructure, growing adoption of precision oncology, and government initiatives to enhance cancer diagnosis and treatment. Expansion of specialized cancer centers is further supporting market growth.
Africa is witnessing steady growth in the stomach cancer market, supported by improving access to cancer care, expanding healthcare infrastructure, and increasing awareness of early diagnosis. Governments and healthcare organizations are strengthening oncology services and investing in diagnostic capabilities to improve patient outcomes. Rising collaborations with international healthcare institutions are expected to create long-term opportunities for the regional market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Acne Treatment Market Size, Share & Growth Graph by 2034
Aesthetic Medicine Market Size, Share, Growth, Analysis, 2034
Anti-Osteoporosis Therapy and Fracture Healing Market Size, 2034
United Arab Emirates Influenza Treatment Market Size, 2034
North America Multiple Electrolytes Injection Market Size by 2034
North America Tulathromycin Market Size & Trends By 2034
We are featured on:
sales@straitsresearch.com